Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06366217
Other study ID # 20-32530A
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2024
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source University of California, San Francisco
Contact Julius Oatts, MD
Phone 415-353-2289
Email Julius.Oatts@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.


Description:

The proposed study strives to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard-of-care (SOC) eye drops in a randomized trial. Primary Aim: Demonstrate non-inferiority of using MydCombi to achieve pupillary dilation compared to standard-of-care eye drops in patients. Participants 2 years or older undergoing standard pupillary dilation will be randomized to use MydCombi in one eye and standard of care pupillary dilation in another eye.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Receiving pupillary dilation in both eyes as part of the participant's standard of care. Exclusion Criteria: - Pupillary or anterior segment abnormality - Participants with pre-existing health conditions that would prevent pupillary dilation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MydCombi Device
ophthalmic spray
Drug:
MydCombi Drug
Tropicamide 1% and phenylephrine HCl 2.5%

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in Spherical equivalent Cycloplegia is the paralysis of the ciliary muscle of the eye resulting in dilatation of the pupil and paralysis of accommodation.
Cycloplegia is defined as the "change score." Change scores were calculated by subtracting the spherical equivalent value after dilation from the value before dilation for each eye.
Before dilation and 30 minutes after dilation
Primary Percent Change in maximum pupil diameter The pupil is the opening in the center of the iris (the structure that gives particpant's eyes their color). The diameter is a straight line passing from side to side through the center of the pupil, which is shaped like a circle. Before dilation and 30 minutes after dilation
Primary Percent Change in pupil constriction percentage Pupillary constriction percentage was calculated by the pupillometer in response to a 180-micro watt flash: (maximum - minimum) / maximum Before and 30 minutes after dilation
Secondary Percent Change in Intraocular Pressure Intraocular pressure is the pressure, or force, inside of the participants eyes. Specifically, it's a measurement of the fluid pressure in the participant's aqueous humor. Before and 30 minutes After Dilation
See also
  Status Clinical Trial Phase
Completed NCT05134974 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) Phase 3
Completed NCT04620213 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis Phase 3
Completed NCT05274321 - Efficacy of the Nanodropper Device on Pupillary Dilation N/A
Completed NCT05223478 - Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Phase 3
Completed NCT04024891 - Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Phase 2